ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...